Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 8, Number 5—May 2002

Perspective

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

Thomas W. Geisbert*, Peter Pushko*, Kevin Anderson*, Jonathan Smith*, Kelly J. Davis*, and Peter B. Jahrling*
Author affiliations: *U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

Main Article

Table 2

Challenge of vaccinated monkeys with Ebola virus (EBOV)

NHP Species Vector Antigen Survival/total Viremic/total Day of deatha
Cynomolgus Replicon GP 0/3 3/3 6, 6, 7
Cynomolgus Replicon NP 0/3 3/3 6, 6, 7
Cynomolgus Replicon GP + NP 0/3 3/3 6, 6, 7
Cynomolgus Replicon Influenza HA 0/3 3/3 6, 6, 7
Cynomolgus Vaccinia GP 0/3 3/3 6, 7, 7
Cynomolgus Liposome Inactivated virion 0/3 3/3 7, 7, 11
Cynomolgus Inactivated virion 0/2 2/2 6, 6
Rhesus Inactivated virion 1/2 2/2 9
Cynomolgus None 0/2 2/2 6, 7
Rhesus None 0/2 2/2 8, 9

aNumber of days after challenge with 1,000 PFU of EBOV.
NHP, nonhuman primate; GP, glycoprotein; NP, nucleoprotein.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO